ArticleACS nano2020
Phospholipase A
Article in ACS nano, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Multi-Omics Profiling of mTBI-Induced Gut-Brain Axis Disruption: A Preliminary Study for Biomarker Screening and Mechanistic Exploration.Biomedicines · 2026Article
- Nanomedicine for chronic pain management: From pathophysiology to engineered drug delivery systems.Materials today. Bio · 2025Review
- Emerging treatments for chronic neuropathic pain from a cross-disease perspective: developments and applications of nanomaterials.The journal of headache and pain · 2025Review
- Pathophysiology-Directed Engineering of a Combination Nanoanalgesic for Neuropathic Pain.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Exploring the potential therapeutic benefits of 7-methoxy coumarin for neuropathy pain: an in vivo, in vitro, and in silico approach.Molecular biology reports · 2024Article
- Combining metabolome and clinical indicators with machine learning provides some promising diagnostic markers to precisely detect smear-positive/negative pulmonary tuberculosis.BMC infectious diseases · 2022Article
- Article
- Mechanism Study on Nanoparticle Negative Surface Charge Modification by Ascorbyl Palmitate and Its Improvement of Tumor Targeting Ability.Molecules (Basel, Switzerland) · 2022Article
- Recent advances in nanoplatforms for the treatment of neuropathic pain.Spinal cord · 2022Review
- The Differential Metabolomes in Cumulus and Mural Granulosa Cells from Human Preovulatory Follicles.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Moderate-Intensity Ultrasound-Triggered On-Demand Analgesia Nanoplatforms for Postoperative Pain Management.International journal of nanomedicine · 2022Article
- Review
- Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris.JCI insight · 2021Article
- Inhibiting spinal secretory phospholipase AMolecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Treating persistent neuropathic pain remains a major clinical challenge. Current conventional treatment approaches carry a substantial risk of toxicity and provide only transient pain relief. In this work, we show that the activity and expression of the inflammatory mediator secretory phospholipase-A
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.